Download PDF
Am J Perinatol 2011; 28(2): 137-144
DOI: 10.1055/s-0030-1263296
© Thieme Medical Publishers

Fetal and Neonatal Alloimmune Thrombocytopenia: Harvesting the Evidence to Develop a Clinical Approach to Management

Amanda Symington1 , Bosco Paes1 , 2
  • 1Hamilton Health Sciences, McMaster Children's Hospital (Neonatal Division), McMaster University, Hamilton, Ontario, Canada
  • 2Department of Pediatrics (Division of Neonatology), McMaster University, Hamilton, Ontario, Canada
Further Information

Publication History

Publication Date:
10 August 2010 (online)

    Permissions and Reprints

ABSTRACT

Neonatal alloimmune thrombocytopenia (NAIT) is the most common cause of severe thrombocytopenia in an otherwise healthy newborn. The most serious complication is intracranial hemorrhage, which can occur either in the fetus or the newborn. Despite the known serious sequelae, both antenatal management and neonatal treatment modalities are plagued by the lack of gold standard evidence to appropriately direct therapy. Maternal, risk-based therapeutic approaches range from invasive protocols to relatively benign noninvasive strategies to avoid serious procedural complications. Intravenous immunoglobulin (IVIG) with or without steroids and fetal blood sampling constitute the mainstay of antenatal management. Neonatal interventions principally focus on the use of antigen-negative compatible or random donor platelets and IVIG. While awaiting the results of controlled trials, each institution must develop a standardized, collaborative, multidisciplinary approach to the screening, diagnostic evaluation, and management of unexpected and anticipated NAIT based on experience, product availability, and emerging scientific data.

KEYWORDS

Maternal - fetal - neonatal - alloimmune thrombocytopenia - management

REFERENCES

  • 1 Burrows R F, Kelton J G. Fetal thrombocytopenia and its relation to maternal thrombocytopenia.  N Engl J Med. 1993;  329 1463-1466
    CrossrefPubMedGoogle Scholar
  • 2 Metcalfe P, Watkins N A, Ouwehand W H et al.. Nomenclature of human platelet antigens.  Vox Sang. 2003;  85 240-245
    CrossrefPubMedGoogle Scholar
  • 3 Gruel Y, Boizard B, Daffos F, Forestier F, Caen J, Wautier J L. Determination of platelet antigens and glycoproteins in the human fetus.  Blood. 1986;  68 488-492
    PubMedGoogle Scholar
  • 4 Blanchette V S, Chen L, de Friedberg Z S, Hogan V A, Trudel E, Décary F. Alloimmunization to the PlA1 platelet antigen: results of a prospective study.  Br J Haematol. 1990;  74 209-215
    CrossrefPubMedGoogle Scholar
  • 5 Doughty H A, Murphy M F, Metcalfe P, Waters A H. Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study.  Br J Haematol. 1995;  90 321-325
    CrossrefPubMedGoogle Scholar
  • 6 Durand-Zaleski I, Schlegel N, Blum-Boisgard C, Uzan S, Dreyfus M, Kaplan C. Immune Thrombocytopenia Working Group . Screening primiparous women and newborns for fetal/neonatal alloimmune thrombocytopenia: a prospective comparison of effectiveness and costs.  Am J Perinatol. 1996;  13 423-431
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Kjeldsen-Kragh J, Killie M K, Tomter G et al.. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia.  Blood. 2007;  110 833-839
    CrossrefPubMedGoogle Scholar
  • 8 Turner M L, Bessos H, Fagge T et al.. Prospective epidemiologic study of the outcome and cost-effectiveness of antenatal screening to detect neonatal alloimmune thrombocytopenia due to anti-HPA-1a.  Transfusion. 2005;  45 1945-1956
    CrossrefPubMedGoogle Scholar
  • 9 Williamson L M, Hackett G, Rennie J et al.. The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1a (PlA1, Zwa) as determined by antenatal screening.  Blood. 1998;  92 2280-2287
    PubMedGoogle Scholar
  • 10 Blanchette V S, Johnson J, Rand M. The management of alloimmune neonatal thrombocytopenia.  Baillieres Best Pract Res Clin Haematol. 2000;  13 365-390
    CrossrefPubMedGoogle Scholar
  • 11 Rayment R, Brunskill S J, Stanworth S, Soothill P W, Roberts D J, Murphy M F. Antenatal interventions for fetomaternal alloimmune thrombocytopenia.  Cochrane Database Syst Rev. 2005;  (1 Issue 1) CD004226
    PubMedGoogle Scholar
  • 12 Mueller-Eckhardt C, Mueller-Eckhardt G, Willen-Ohff H et al.. Immunogenicity of and immune response to the human platelet antigen Zwa is strongly associated with HLA-B8 and DR3.  Tissue Antigens. 1985;  26 71-76
    CrossrefPubMedGoogle Scholar
  • 13 Davoren A, McParland P, Crowley J, Barnes A, Kelly G, Murphy W G. Antenatal screening for human platelet antigen-1a: results of a prospective study at a large maternity hospital in Ireland.  BJOG. 2003;  110 492-496
    PubMedGoogle Scholar
  • 14 Maslanka K, Guz K, Zupanska B. Antenatal screening of unselected pregnant women for HPA-1a antigen, antibody and alloimmune thrombocytopenia.  Vox Sang. 2003;  85 326-327
    CrossrefPubMedGoogle Scholar
  • 15 Dreyfus M, Kaplan C, Verdy E, Schlegel N, Durand-Zaleski I, Tchernia G. Immune Thrombocytopenia Working Group . Frequency of immune thrombocytopenia in newborns: a prospective study.  Blood. 1997;  89 4402-4406
    PubMedGoogle Scholar
  • 16 de Moerloose P, Boehlen F, Extermann P, Hohfeld P. Neonatal thrombocytopenia: incidence and characterization of maternal antiplatelet antibodies by MAIPA assay.  Br J Haematol. 1998;  100 735-740
    CrossrefPubMedGoogle Scholar
  • 17 Uhrynowska M, Niznikowska-Marks M, Zupańska B. Neonatal and maternal thrombocytopenia: incidence and immune background.  Eur J Haematol. 2000;  64 42-46
    CrossrefPubMedGoogle Scholar
  • 18 Ghevaert C, Campbell K, Walton J et al.. Management and outcome of 200 cases of fetomaternal alloimmune thrombocytopenia.  Transfusion. 2007;  47 901-910
    CrossrefPubMedGoogle Scholar
  • 19 Bussel J B, Zabusky M R, Berkowitz R L, McFarland J G. Fetal alloimmune thrombocytopenia.  N Engl J Med. 1997;  337 22-26
    CrossrefPubMedGoogle Scholar
  • 20 Spencer J A, Burrows R F. Feto-maternal alloimmune thrombocytopenia: a literature review and statistical analysis.  Aust N Z J Obstet Gynaecol. 2001;  41 45-55
    CrossrefPubMedGoogle Scholar
  • 21 Killie M K, Husebekk A, Kjeldsen-Kragh J, Skogen B. A prospective study of maternal anti-HPA 1a antibody level as a potential predictor of alloimmune thrombocytopenia in the newborn.  Haematologica. 2008;  93 870-877
    CrossrefPubMedGoogle Scholar
  • 22 Skogen B, Husebekk A, Killie M K, Kjeldsen-Kragh J. Neonatal alloimmune thrombocytopenia is not what it was: a lesson learned from a large prospective screening and intervention program.  Scand J Immunol. 2009;  70 531-534
    CrossrefPubMedGoogle Scholar
  • 23 Radder C M, Brand A, Kanhai H HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it?.  Vox Sang. 2003;  84 318-325
    CrossrefPubMedGoogle Scholar
  • 24 Kanhai H HH, Porcelijn L, Engelfriet C P et al.. Management of alloimmune thrombocytopenia.  Vox Sang. 2007;  93 370-385
    PubMedGoogle Scholar
  • 25 Kjeldsen-Kragh J, Husebekk A, Killie M K, Skogen B. Is it time to include screening for neonatal alloimmune thrombocytopenia in the general antenatal health care programme?.  Transfus Apher Sci. 2008;  38 183-188
    CrossrefPubMedGoogle Scholar
  • 26 Fretheim A. Cost-effectiveness analysis of screening for neonatal alloimmune thrombocytopenia was based on invalid assumption.  BJOG. 2008;  115 412-413 author reply 413-414, discussion 414
    PubMedGoogle Scholar
  • 27 Killie M K, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen J A, Kristiansen I S. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia.  BJOG. 2007;  114 588-595
    PubMedGoogle Scholar
  • 28 Kiefel V, Santoso S, Weisheit M, Müeller-Eckhardt C. Monoclonal antibody—specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies.  Blood. 1987;  70 1722-1726
    PubMedGoogle Scholar
  • 29 Arnold D M, Smith J W, Kelton J G. Diagnosis and management of neonatal alloimmune thrombocytopenia.  Transfus Med Rev. 2008;  22 255-267
    CrossrefPubMedGoogle Scholar
  • 30 Kaplan C, Daffos F, Forestier F et al.. Management of alloimmune thrombocytopenia: antenatal diagnosis and in utero transfusion of maternal platelets.  Blood. 1988;  72 340-343
    PubMedGoogle Scholar
  • 31 Overton T G, Duncan K R, Jolly M, Letsky E, Fisk N M. Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome.  Am J Obstet Gynecol. 2002;  186 826-831
    CrossrefPubMedGoogle Scholar
  • 32 Daffos F, Forestier F, Muller J Y et al.. Prenatal treatment of alloimmune thrombocytopenia.  Lancet. 1984;  2 632
    PubMedGoogle Scholar
  • 33 Nicolini U, Rodeck C H, Kochenour N K et al.. In-utero platelet transfusion for alloimmune thrombocytopenia.  Lancet. 1988;  2 506
    PubMedGoogle Scholar
  • 34 Birchall J E, Murphy M F, Kaplan C, Kroll H. European Fetomaternal Alloimmune Thrombocytopenia Study Group . European collaborative study of the antenatal management of feto-maternal alloimmune thrombocytopenia.  Br J Haematol. 2003;  122 275-288
    CrossrefPubMedGoogle Scholar
  • 35 van den Akker E S, Oepkes D, Lopriore E, Brand A, Kanhai H H. Noninvasive antenatal management of fetal and neonatal alloimmune thrombocytopenia: safe and effective.  BJOG. 2007;  114 469-473
    CrossrefPubMedGoogle Scholar
  • 36 Paidas M J, Berkowitz R L, Lynch L et al.. Alloimmune thrombocytopenia: fetal and neonatal losses related to cordocentesis.  Am J Obstet Gynecol. 1995;  172 (2 Pt 1) 475-479
    CrossrefPubMedGoogle Scholar
  • 37 Simon H U, Späth P J. IVIG—mechanisms of action.  Allergy. 2003;  58 543-552
    CrossrefPubMedGoogle Scholar
  • 38 Koleba T, Ensom M HH. Pharmacokinetics of intravenous immunoglobulin: a systematic review.  Pharmacotherapy. 2006;  26 813-827
    CrossrefPubMedGoogle Scholar
  • 39 Bussel J B, Berkowitz R L, Lynch L et al.. Antenatal management of alloimmune thrombocytopenia with intravenous γ-globulin: a randomized trial of the addition of low-dose steroid to intravenous γ-globulin.  Am J Obstet Gynecol. 1996;  174 1414-1423
    CrossrefPubMedGoogle Scholar
  • 40 Berkowitz R L, Kolb E A, McFarland J G et al.. Parallel randomized trials of risk-based therapy for fetal alloimmune thrombocytopenia.  Obstet Gynecol. 2006;  107 91-96
    CrossrefPubMedGoogle Scholar
  • 41 Berkowitz R L, Lesser M L, McFarland J G et al.. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial.  Obstet Gynecol. 2007;  110 (2 Pt 1) 249-255
    CrossrefPubMedGoogle Scholar
  • 42 van den Akker E, Oepkes D, Brand A, Kanhai H H. Vaginal delivery for fetuses at risk of alloimmune thrombocytopenia?.  BJOG. 2006;  113 781-783
    CrossrefPubMedGoogle Scholar
  • 43 Bassler D, Greinacher A, Okascharoen C et al.. A systematic review and survey of the management of unexpected neonatal alloimmune thrombocytopenia.  Transfusion. 2008;  48 92-98
    PubMedGoogle Scholar
  • 44 Ouwehand W H, Smith G, Ranasinghe E. Management of severe alloimmune thrombocytopenia in the newborn.  Arch Dis Child Fetal Neonatal Ed. 2000;  82 F173-F175
    CrossrefPubMedGoogle Scholar
  • 45 Bussel J B, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates.  Blood Rev. 2008;  22 33-52
    CrossrefPubMedGoogle Scholar
  • 46 Mueller-Eckhardt C, Kiefel V, Grubert A et al.. 348 cases of suspected neonatal alloimmune thrombocytopenia.  Lancet. 1989;  1 363-366
    PubMedGoogle Scholar
  • 47 Kiefel V, Bassler D, Kroll H et al.. Antigen-positive platelet transfusion in neonatal alloimmune thrombocytopenia (NAIT).  Blood. 2006;  107 3761-3763
    CrossrefPubMedGoogle Scholar
  • 48 Win N. Provision of random-donor platelets (HPA-1a positive) in neonatal alloimmune thrombocytopenia due to anti HPA-1a alloantibodies.  Vox Sang. 1996;  71 130-131
    CrossrefPubMedGoogle Scholar
  • 49 Allen D, Verjee S, Rees S, Murphy M F, Roberts D J. Platelet transfusion in neonatal alloimmune thrombocytopenia.  Blood. 2007;  109 388-389
    CrossrefPubMedGoogle Scholar
  • 50 Bakchoul T, Sachs U J, Wittekindt B, Sclösser R, Bein G, Santoso S. Treatment of fetomaternal neonatal alloimmune thrombocytopenia with random platelets.  Pediatr Blood Cancer. 2008;  50 1293-1294
    CrossrefPubMedGoogle Scholar
  • 51 Derycke M, Dreyfus M, Ropert J C, Tchernia G. Intravenous immunoglobulin for neonatal isoimmune thrombocytopenia.  Arch Dis Child. 1985;  60 667-669
    CrossrefPubMedGoogle Scholar
  • 52 Sidiropoulos D, Straume B. The treatment of neonatal isoimmune thrombocytopenia with intravenous immunoglobin (IgG i.v.)  Blut. 1984;  48 383-386
    CrossrefPubMedGoogle Scholar
  • 53 Suarez C R, Anderson C. High-dose intravenous gammaglobulin (IVG) in neonatal immune thrombocytopenia.  Am J Hematol. 1987;  26 247-253
    CrossrefPubMedGoogle Scholar
  • 54 Ballin A, Andrew M, Ling E, Perlman M, Blanchette V. High-dose intravenous gammaglobulin therapy for neonatal autoimmune thrombocytopenia.  J Pediatr. 1988;  112 789-792
    PubMedGoogle Scholar
  • 55 Linder N, Shapiro S C, Moser A M, Roitman J, Engelhard D. Treatment of neonatal immune thrombocytopenia with high dose intravenous γ-globulin.  Dev Pharmacol Ther. 1990;  14 205-208
    PubMedGoogle Scholar

Bosco A PaesM.B.B.S. F.R.C.P.I. F.R.C.P.C. 

McMaster Children's Hospital (Room 3A)

1200 Main Street West, Hamilton, Ontario L8S 4J9, Canada

Email: paes@mcmaster.ca

      >